Metraipolis › archive › dc_ea2bed921b00

Antonio Lanzavecchia — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Antonio_Lanzavecchia
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-09T15:27:25.170Z
SHA-256 of the archived text
dafc9b57c3df701b1a79ad34c8b4c39ebc4e7a3b5f2c863575279e86ca4465a1
Stable URL of this page
https://metraipolis.com/documento/dc_ea2bed921b00

How to cite

Antonio Lanzavecchia — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Antonio_Lanzavecchia (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_ea2bed921b00 (Metraipolis archive dc_ea2bed921b00, sha256 dafc9b57c3df701b1a79ad34c8b4c39ebc4e7a3b5f2c863575279e86ca4465a1)
BibTeX
@misc{dcea2bed921b00,
  title = {Antonio Lanzavecchia — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Antonio_Lanzavecchia},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_ea2bed921b00; sha256 dafc9b57c3df701b1a79ad34c8b4c39ebc4e7a3b5f2c863575279e86ca4465a1},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Antonio_Lanzavecchia. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Antonio Lanzavecchia (born 9 October 1951) is an Italian immunologist. He heads the Human Immunology Program at the Istituto Nazionale di Genetica Molecolare (INGM) in Milan. He worked in Switzerland for most of his career: from 1983 to 1999 at the Basel Institute for Immunology, from 1999 to 2020 as founding director of the Institute for Research in Biomedicine (IRB) in Bellinzona, as professor of human immunology at ETH Zurich from 2009 to 2017, where he is professor emeritus, and thereafter at the Faculty of Biomedical Sciences of the Università della Svizzera italiana. He is the scientific founder of the antibody company Humabs BioMed, acquired by Vir Biotechnology in 2017, where he was senior vice-president and senior research fellow until 2026. Working almost exclusively with human cells, Lanzavecchia showed that B cells capture and present antigen to helper T cells, introduced the derivation of dendritic cells from blood monocytes and defined their maturation programme, proposed the serial-triggering model of T cell receptor signalling, and identified central and effector memory T cells. From 2003 his laboratory developed methods to interrogate human memory B cells and plasma cells at high throughput, yielding broadly neutralising antibodies against influenza viruses, cytomegalovirus, coronaviruses and Ebola virus, and the discovery that antibodies raised against Plasmodium falciparum can acquire whole receptor domains by templated DNA insertion.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Antonio Lanzavecchia» — https://en.wikipedia.org/wiki/Antonio_Lanzavecchia
Wikidata Q4776729: «Italian immunologist» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q4776729
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Antonio_Lanzavecchia?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1380985948, consultata il 2026-11-09T15:24:05.695Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 62a839ed12b9ad1845e48a12fb8180ddd119fa99cc7c8bc73fa6cd251886c431